CONCEPT OF PHARMACOVIGILANCE & IT'S ROLE IN ADVERSE DRUG REACTION (ADR) MANAGEMENT

Ankit Maurya, Divyanshu Yadav, Vikash Yadav, Manshi Jaiswal, Krishnanand Prajapati

Nirmala Devi Pharmacy College, Jaunpur

Abstract

In order to guarantee the safe and efficient use of medications, pharmacovigilance is an essential area of healthcare that focuses on the identification, evaluation, comprehension, and prevention of adverse drug reactions (ADRs). It has changed dramatically throughout time, especially in the wake of large drug safety incidents, and is currently backed by national and international monitoring programs like the Pharmacovigilance Programme of India and the WHO Programme for International Drug Monitoring. The main ideas of pharmacovigilance, categories of adverse drug reactions (ADRs), detection and reporting techniques, causality assessment tools, and the function of regulatory bodies in drug safety monitoring are all highlighted in this overview. It also covers contemporary developments that have increased the effectiveness of ADR detection, such as data mining, artificial intelligence, electronic health records, and mobile reporting systems. Notwithstanding these advancements, problems including underreporting, ignorance, poor data quality, and resource constraints still exist, particularly in poorer nations. The study highlights that increasing drug safety and patient outcomes requires bolstering pharmacovigilance through international cooperation, technology integration, and active patient and healthcare professional participation.

Keywords: *Pharmacovigilance; Adverse drug reactions (ADRs); Drug safety; Signal detection; Causality assessment; WHO-UMC scale*

Corresponding Author
Ankit Maurya
Received: 25/04/2026
Revised: 02/05/2026
Accepted: 07/05/2026
DOI: http://doi.org/10.66204/GJPSR-746-2026-2-5-4

How to Cite
Maurya A, Yadav D, Yadav V, Jaiswal M, Prajapati K. Concept of pharmacovigilance & its role in adverse drug reaction (ADR) management. *Global Journal of Pharmaceutical and Scientific Research*. 2026, ISSN: 3108-0103. 2026;2(5):746–769. ISSN: 3108-0103. http://doi.org/10.66204/GJPSR-746-2026-2-5-4

1. INTRODUCTION

Modern healthcare relies heavily on the safe and efficient use of medications, but no medication is risk-free. Increased hospital admissions, longer hospital stays, and high healthcare expenditures are all consequences of adverse drug reactions (ADRs), which continue to be a major source of morbidity and mortality globally (Pirmohamed et al., 2004; Lazarou et al., 1998). In this regard, pharmacovigilance has become a crucial field devoted to guaranteeing medication safety by methodically tracking, identifying, evaluating, and preventing negative effects linked to pharmaceuticals.

Following significant drug-related tragedies, most notably the Thalidomide tragedy, which revealed grave flaws in pre-marketing safety evaluation, the idea of pharmacovigilance attracted international attention. This incident brought to light the necessity of ongoing drug monitoring even after approval, which prompted the development of organized pharmacovigilance programs and regulatory frameworks across the globe (McBride, 1961; Vargesson, 2015). Since then, pharmacovigilance has developed into an all-encompassing approach that incorporates public health, regulatory research, and clinical practice.

The World Health Organization defines pharmacovigilance as any activity pertaining to the identification, evaluation, comprehension, and avoidance of side effects or any other drug-related issues (WHO, 2002). Spontaneous reporting of adverse drug reactions (ADRs), signal detection, causality analysis, risk-benefit analysis, and the application of risk-reduction techniques are some of these activities. Pharmacovigilance systems involve cooperation between patients, pharmaceutical companies, regulatory bodies, and healthcare professionals at the international, national, and institutional levels.

Organ toxicity, hypersensitivity reactions, and even death are examples of severe, life-threatening illnesses that can result from adverse drug reactions (ADRs). The risk of adverse drug reactions (ADRs) has increased due to the growing complexity of drug therapy, which includes polypharmacy, the use of biologics, and customized medicine methods. The frequency and intensity of adverse responses are also influenced by variations in patient factors, including age, genetics, comorbidities, and concurrent drugs (Edwards & Aronson, 2000; Routledge et al., 2004).

By permitting prompt regulatory responses, encouraging the sensible use of medications, and enabling the early detection of safety signals, pharmacovigilance plays a critical role in the management of adverse drug reactions. It assists regulatory bodies in ensuring that the advantages of medications outweigh their hazards and supports medical professionals in making well-informed clinical judgments. Additionally, by giving pharmaceutical companies

input and directing post-marketing research, pharmacovigilance helps create safer medications (Waller, 2017).

By increasing the effectiveness and precision of ADR detection, technology developments like artificial intelligence, big data analytics, and electronic health records have reinforced pharmacovigilance systems in recent years. However, problems including underreporting, poor data quality, and low awareness still have an impact on how well these systems work, especially in poorer nations (Bate & Hobbiger, 2021; Alshammari & Alshakka, 2020).

The goal of this study is to give a thorough overview of pharmacovigilance and its vital role in managing adverse drug reactions. The historical development, important ideas, ADR detection techniques, causality evaluation, pharmacovigilance systems, difficulties, and prospects for the future are all covered. This analysis highlights the necessity of ongoing efforts to improve patient outcomes and bolster medication safety monitoring by emphasizing the significance of pharmacovigilance.

2. Historical Evolution of Pharmacovigilance

2.1 Early Drug Disasters

Major drug-related tragedies that revealed flaws in early drug safety systems had a significant impact on the creation of pharmacovigilance. The Thalidomide catastrophe, which signaled a shift in international drug regulation, was the most important of these. Drug approval procedures were less strict in the 1960s, with less safety testing and no organized post-marketing monitoring (Strom et al., 2019; Edwards, 2017).

When thalidomide was first used as a sedative for expectant mothers in the late 1950s, it was discovered that it could result in serious birth defects, such as phocomelia. Over 10,000 newborns in several nations were impacted; many of them died or had permanent disabilities (McBride, 1961; Lenz, 1962; Vargesson, 2015).

The shortcomings of preclinical testing and the absence of ADR monitoring mechanisms were brought to light by this tragedy. It resulted in significant regulatory changes, including as the United States' Kefauver–Harris Amendments (1962), which required evidence of a drug's efficacy and safety prior to approval (Carpenter, 2010). Additionally, by highlighting the necessity of ongoing medication safety monitoring, it helped build international pharmacovigilance systems (World Health Organization, 2002; Edwards & Aronson, 2000).

2.2 Development of International Drug Monitoring Systems

Following the thalidomide tragedy, it became clear that worldwide cooperation in drug safety monitoring was necessary because national systems were unable to identify uncommon adverse drug reactions on their own. To encourage coordinated ADR reporting and data

sharing, the World Health Organization launched a global drug monitoring program in 1968 (World Health Organization, 2002; Olsson, 1998).

Individual Case Safety Reports (ICSRs) and other structured international networks with specified reporting formats developed from early spontaneous reporting systems. Signal identification and risk assessment were enhanced by the creation of centralized databases and the use of statistical techniques (Bate & Edwards, 2006; Hauben & Aronson, 2007).

By improving cooperation between regulatory bodies and medical practitioners, these global platforms made it possible to promptly identify safety issues and carry out regulatory measures. Global pharmacovigilance has therefore improved in terms of guaranteeing patient safety and sensible medication usage (Edwards, 2017; Strom et al., 2019).

2.3 Role of World Health Organization Programme

A crucial part of global pharmacovigilance, the World Health Organization Programme for International Drug Monitoring was founded in 1968 with the goal of enhancing patient safety by identifying, evaluating, and preventing adverse drug reactions (ADRs). By allowing member nations to exchange safety data and improve their own pharmacovigilance systems, it fosters international cooperation (World Health Organization, 2002; Lindquist, 2008).

The Uppsala Monitoring Center's VigiBase, which houses millions of Individual Case Safety Reports (ICSRs) and facilitates signal discovery using sophisticated data analysis methods, is a key component of the program (Lindquist, 2008; Bate & Edwards, 2006).

Additionally, the initiative emphasizes capacity building by supporting uniform reporting processes and offering training, guidelines, and technical assistance, especially for developing nations. Furthermore, it makes it easier for stakeholders all over the world to receive drug safety information on time, which supports efficient risk management and regulatory decision-making (Edwards, 2017; Strom et al., 2019).



Figure 1: Evolution of Pharmacovigilance System

3. Basic Concepts in Pharmacovigilance

To effectively monitor, detect, and prevent adverse drug reactions (ADRs), one must have a thorough understanding of the basic concepts of pharmacovigilance. These ideas offer the theoretical and practical foundation for guaranteeing drug safety and maximizing therapeutic results.

3.1 Definitions and Terminology

The World Health Organization defines pharmacovigilance as "the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems" (WHO, 2002). According to Edwards and Aronson (2000), an adverse drug reaction (ADR) is a negative and unexpected reaction to a medication that happens at standard dosages when it is used for treatment, diagnosis, or prevention.

Other key terms include risk factor (a feature that raises the possibility of an ADR), signal (information indicating a new or known adverse event that may be caused by a medicine), and adverse event (any unfavorable medical occurrence not necessarily causally related to therapy). To guarantee uniformity in ADR reporting and analysis, standardized terminology systems like MedDRA are frequently employed (Hauben & Aronson, 2007; WHO, 2002).

3.2 Types of Adverse Drug Reactions (Type A–F)

Based on their traits and processes, ADRs are often divided into six kinds (Type A–F). Type A (Augmented) reactions, like insulin-induced hypoglycemia, are dose-dependent, predictable, and frequently associated with the drug's pharmacological activity. Type B (Bizarre) reactions, like penicillin-induced anaphylaxis, are unpredictable, not dose-dependent, and frequently involve immunological or idiosyncratic mechanisms (Rawlins & Thompson, 1977; Edwards & Aronson, 2000).

Long-term drug use is linked to Type C (chronic) reactions, whereas Type D (delayed) reactions, such as teratogenic or carcinogenic consequences, manifest after extended exposure or even after stopping a medication. Type E (End-of-use) reactions, such as opioid withdrawal symptoms, happen when a drug is stopped. Unexpected therapeutic failure, frequently brought on by medication interactions or resistance, is known as a type F (failure) reaction (Edwards & Aronson, 2000; Waller & Evans, 2003). Clinicians can more effectively recognize, anticipate, and manage adverse drug reactions (ADRs) thanks to this classification.

Table 1: Classification of Adverse Drug Reactions (ADRs)

Type of ADR	Description	Example
Type A (Augmented)	Dose-dependent, predictable	Hypoglycemia with insulin
Type B (Bizarre)	Idiosyncratic, unpredictable	Anaphylaxis to penicillin

Type C (Chronic)	Due to long-term use	Steroid-induced osteoporosis
Type D (Delayed)	Delayed onset effects	Carcinogenesis
Type E (End of use)	Withdrawal reactions	Opioid withdrawal
Type F (Failure)	Unexpected therapeutic failure	Antibiotic resistance

3.3 Classification Based on Severity and Seriousness

ADRs can also be categorized according to seriousness and severity (mild, moderate, and severe). The level of the reaction is referred to as its severity; it can range from minor symptoms that need little treatment to severe reactions that could be fatal. Conversely, the regulatory definition of seriousness include outcomes including death, life-threatening diseases, hospitalization, disability, congenital malformations, or other medically significant events (ICH, 2003; Edwards & Aronson, 2000).

For proper clinical management and regulatory reporting, it is essential to comprehend the difference between severity and seriousness. Serious adverse drug reactions (ADRs) must be reported right once to regulatory bodies and may result in labeling modifications, usage limitations, or removal from the market (WHO, 2002; ICH, 2003).

3.4 Risk–Benefit Assessment

A key idea in pharmacovigilance is risk-benefit assessment, which weighs a drug's potential hazards against its therapeutic advantages. This dynamic evaluation is carried out at every stage of a pharmaceutical product's lifecycle, from post-marketing surveillance to clinical trials. If a drug's advantages outweigh the dangers for the target group, it is deemed suitable for use (Edwards & Aronson, 2000; Strom et al., 2019).

By offering actual data on medication safety, pharmacovigilance operations greatly aid in risk-benefit analysis. The ratio of risk to benefit can be affected by a number of factors, including genetic variability, comorbidities, drug interactions, and patient characteristics. This data is used by regulatory bodies to carry out risk-reduction tactics, including as dosage modifications, contraindications, and safety alerts (Waller & Evans, 2003; WHO, 2002).

3.5 Signal Detection and Management

A key component of pharmacovigilance is signal detection, which is the process of finding novel or before unknown side effects linked to a medication. According to Hauben and Aronson (2007), a signal is information that has been published that points to a possible causative link between a medication and an adverse event and calls for additional research.

Large databases and statistical data mining techniques are used by contemporary pharmacovigilance systems to identify signals from spontaneous reporting systems. After

being found, signals are validated, prioritized, and thoroughly evaluated to ascertain their clinical importance. Signal identification, validation, confirmation, analysis, and regulatory action are some of the procedures that make up signal management (Bate & Edwards, 2006; Edwards, 2017).

Timely identification of safety issues and the adoption of suitable regulatory steps, such as revising product information, sending out safety alerts, or limiting drug usage, are ensured by effective signal management. This procedure is essential for improving the safe use of medications and protecting public health (WHO, 2002; Strom et al., 2019).

4. Pharmacovigilance Systems and Programs

Pharmacovigilance systems are organized frameworks created to guarantee ongoing drug safety monitoring at various phases of a medication's lifespan. To identify, evaluate, and stop adverse drug reactions (ADRs), these systems include international cooperation, national implementation, and regulatory supervision. By enabling prompt identification of drug-related risks and supporting evidence-based regulatory choices, the development of these systems has greatly improved patient safety (Banerjee & Mondal, 2019; Hartigan-Go, 2018).

4.1 Global Pharmacovigilance Systems

Global pharmacovigilance systems are crucial for spotting uncommon and dangerous adverse drug reactions that would go undetected in individual nations. A global framework created by the World Health Organization enables member nations to work together to monitor drug safety. This international network facilitates the gathering and evaluation of ADR data from various populations, improving the identification of possible safety alerts (Hartigan-Go, 2018; Lindquist, 2008).

By using statistical techniques like disproportionality analysis, the integration of massive worldwide databases has greatly enhanced signal detecting capabilities. Additionally, these systems make it possible for safety issues to be communicated quickly, allowing regulatory bodies around the world to act quickly as needed. Additionally, consistent reporting procedures have improved data quality and consistency across nations thanks to harmonization work spearheaded by groups like the International Council for Harmonization (ICH) (Wisniewski et al., 2020; ICH, 2016).

4.2 National Programs

The foundation of drug safety monitoring in each nation is provided by national pharmacovigilance programs. The Pharmacovigilance Programme of India is essential for gathering, evaluating, and reporting adverse drug reactions in India. PvPI was founded under the Ministry of Health and Family Welfare and functions via a network of ADR Monitoring

Centers (AMCs) situated in hospitals and medical schools around the nation (Sharma et al., 2017).

The initiative promotes patients' and healthcare providers' spontaneous reporting, which improves the identification of ADRs that were previously unknown. Additionally, it emphasizes training initiatives and awareness efforts to raise reporting rates and data quality. In order to support global pharmacovigilance initiatives, the gathered data is evaluated at the national level and shared with worldwide databases. Furthermore, by offering data on medication safety in the Indian population, PvPI aids in regulatory decision-making (Singh et al., 2018; Kalaiselvan et al., 2019).

4.3 Regulatory Authorities

By ensuring that pharmaceuticals on the market adhere to safety regulations, regulatory bodies play a crucial part in pharmacovigilance. The US Food and Drug Administration runs programs like FAERS to track adverse occurrences and is in charge of post-marketing monitoring in the US. It assesses safety information and carries out regulatory measures such label updates, drug recalls when required, and risk evaluation and mitigation strategies (REMS) (Dal Pan, 2012; FDA, 2020).

In a similar vein, the European Medicines Agency uses programs like EudraVigilance to supervise pharmacovigilance efforts within the EU. By giving the public access to safety data, the EMA guarantees transparency and facilitates safety monitoring among member states. Additionally, it is essential for risk management and signal detection, collaborating closely with national regulatory bodies to guarantee uniform regulatory choices (Kurz & Van Erps, 2017; EMA, 2021).

These multinational regulatory organizations work together to improve medication safety standards and standardize pharmacovigilance procedures. They play a crucial part in converting pharmacovigilance data into practical regulatory choices that safeguard public health.

4.4 Role of Uppsala Monitoring Centre

Under the WHO Programme for International Drug Monitoring, the Uppsala Monitoring Centre (UMC) is the worldwide coordinating point for pharmacovigilance initiatives. It is in charge of overseeing VigiBase, an international database of Individual Case Safety Reports (ICSRs) that includes millions of ADR reports from participating nations (Lindquist, 2008; Bergvall et al., 2014).

By using sophisticated data mining methods and statistical models to find any medication safety problems, UMC plays a crucial part in signal detection. Additionally, it creates

recommendations and tools to standardize pharmacovigilance procedures globally. Additionally, UMC strengthens national pharmacovigilance centers' ability to monitor drug safety by offering them technical assistance and training, especially in low- and middle-income nations (Bergvall et al., 2014; Olsson et al., 2019).

Additionally, by promoting cooperative research projects and sharing safety information, UMC promotes international communication. Its contributions have greatly improved pharmacovigilance systems' efficacy and efficiency, making it a crucial component in guaranteeing the safe use of medications throughout the world.

5. Methods of ADR Detection and Reporting

Pharmacovigilance relies heavily on the identification and reporting of adverse drug reactions (ADRs). Drug-related hazards are identified, assessed, and tracked using a range of methodological techniques in various clinical contexts and demographics. While each approach has unique advantages and disadvantages, when combined, they offer a thorough framework for guaranteeing medication safety throughout the product lifecycle (Aronson, 2012; Golder et al., 2011).

5.1 Spontaneous Reporting Systems

The most popular technique for identifying adverse drug reactions (ADRs), especially uncommon and unexpected events, is spontaneous reporting systems (SRS). These systems depend on pharmaceutical corporations, patients, and medical professionals voluntarily reporting suspected adverse drug reactions (ADRs) to national or worldwide pharmacovigilance centers. Systems like FAERS and EudraVigilance are two examples (Hazell & Shakir, 2006).

The capacity of SRS to produce early safety signals is their main benefit, particularly for recently approved medications. However, they have drawbacks that make it challenging to determine the actual prevalence of ADRs, including underreporting, reporting bias, and a lack of denominator data. Despite these difficulties, spontaneous reporting continues to be an essential component of post-marketing surveillance and pharmacovigilance (Lopez-Gonzalez et al., 2009; Hazell & Shakir, 2006).

5.2 Cohort Event Monitoring

An active surveillance technique called Cohort Event Monitoring (CEM) entails the prospective follow-up of a cohort of patients who have been exposed to a certain medication. Regardless of presumed causality, all adverse events are documented and patients are tracked throughout time. Compared to spontaneous reporting, this method yields more thorough and organized data (Mann & Andrews, 2007).

Because it makes it possible to estimate incidence rates and identify risk variables linked to adverse drug reactions (ADRs), CEM is especially helpful for recently approved medications and public health initiatives. However, it can be resource-intensive and necessitates patient follow-up procedures and well-organized data collection systems. Despite these difficulties, CEM provides insightful information about medication safety in actual clinical settings (WHO, 2012; Mann & Andrews, 2007).

5.3 Case-Control and Observational Studies

Pharmacovigilance frequently uses case-control and other observational studies to look at relationships between adverse outcomes and drug exposure. In case-control studies, prior drug exposure is evaluated by comparing patients who experience a particular adverse event (cases) with those who do not (controls). These studies are especially helpful for identifying potential risk factors and researching uncommon adverse occurrences (Strom & Kimmel, 2019).

By examining actual data, other observational designs like cross-sectional and retrospective cohort studies also aid in the identification of ADRs. These techniques enable researchers to assess medication safety in a variety of clinical situations and huge populations. They must be carefully considered throughout study design and analysis, though, as they may be susceptible to bias and confounding variables (Schneeweiss & Avorn, 2005; Strom et al., 2019).

5.4 Electronic Health Records and Databases

Pharmacovigilance skills have been greatly improved by the use of electronic health records (EHRs) and huge healthcare databases. More thorough research of drug safety is made possible by these data sources, which offer comprehensive information on patient demographics, medication prescriptions, clinical outcomes, and comorbidities (Hripcsak et al., 2015).

In order to find patterns of adverse occurrences and identify safety alerts, advanced analytical techniques like as data mining and machine learning are rapidly being applied to EHR data. These devices can supplement conventional pharmacovigilance techniques and enable real-time monitoring. To maximize their efficacy, however, issues including data quality, interoperability, and privacy concerns must be resolved (Coloma et al., 2013; Hripcsak et al., 2015).

5.5 Role of Healthcare Professionals and Patients

Physicians, pharmacists, and nurses are among the healthcare professionals who are crucial in identifying and reporting adverse drug reactions. Their clinical knowledge guarantees

accurate and prompt reporting to pharmacovigilance systems and makes it possible to identify suspected drug-related issues. To increase reporting rates and improve the quality of ADR data, training and awareness initiatives are crucial (Toklu & Uysal, 2008).

Patient participation in pharmacovigilance has become more widely acknowledged in recent years. Patient reporting offers important information on medication safety, especially when it comes to how adverse drug reactions (ADRs) affect quality of life and medication compliance. Direct patient reporting systems, which supplement information from medical experts and advance a more thorough understanding of drug safety, have been implemented in many nations (Inácio et al., 2017; Avery et al., 2011).

To ensure the safe and efficient use of medications and to develop pharmacovigilance systems, patients and healthcare professionals must work together. In contemporary drug safety monitoring, promoting active involvement and enhancing reporting systems continue to be top priorities.

Table 2: Comparison of ADR Detection Methods

Method	Type	Strengths	Limitations
Spontaneous Reporting	Passive	Simple, low cost	Underreporting
Cohort Event Monitoring	Active	Accurate incidence	Resource intensive
Case-Control Studies	Observational	Good for rare ADRs	Recall bias
EHR & Databases	Digital	Large data, real-world evidence	Data quality issues
Patient Reporting	Participatory	Captures real experience	Subjective



Figure 2: Workflow of Pharmacovigilance System

6. Causality Assessment of ADRs

A crucial facet of pharmacovigilance is causality evaluation, which aims to ascertain the probability that a certain medication is to blame for an adverse drug response (ADR). Accurate signal detection, regulatory decision-making, and patient care all depend on establishing causation. Structured assessment techniques are necessary to assure objective evaluation because ADRs can result from a variety of reasons, including underlying disorders, concurrent drugs, or patient-specific characteristics (Edwards & Aronson, 2000; Agbabiaka et al., 2008).

6.1 Importance of Causality Assessment

To differentiate genuine ADRs from coincidental occurrences, causality assessment is essential. It aids medical professionals and regulatory bodies in deciding whether to keep, stop, or alter a medication. In order to produce trustworthy safety data, which serves as the foundation for signal identification and risk-benefit analysis, accurate causality assessment is also necessary (Agbabiaka et al., 2008).

By directing therapeutic choices and averting additional harm, causality evaluation in clinical practice improves customized patient care. It guarantees that only legitimate and clinically significant ADRs are added to pharmacovigilance databases from a regulatory standpoint. In the end, this procedure improves the caliber of safety reports and makes it easier to take the

proper regulatory actions, such updating labels or withdrawing drugs (Macedo et al., 2006; Edwards & Aronson, 2000).

6.2 WHO-UMC Scale

One of the most used techniques for assessing ADRs is the WHO-UMC causality evaluation system, which was created by the World Health Organization in association with the Uppsala Monitoring Center. Certain, probable/likely, possible, unlikely, conditional/unclassified, and unassessable/unclassifiable are the preset categories into which this method divides the association between a medication and an adverse event (WHO-UMC, 2018).

In addition to taking into account variables like temporal association, response to drug withdrawal (dechallenge), response to re-administration (rechallenge), alternative explanations, and prior knowledge of the reaction, the WHO-UMC scale is based on clinical judgment. It is appropriate for both large-scale pharmacovigilance initiatives and normal clinical practice due to its simplicity and adaptability. However, due to the assessment's subjective nature, evaluators may differ from one another (Theophile et al., 2013; WHO-UMC, 2018).

6.3 Naranjo Algorithm

A structured, questionnaire-based technique called the Naranjo Algorithm was created to standardize the evaluation of causation. It consists of ten questions that assess things like drug levels, dose-response relationship, temporal correlation, alternative causes, and prior patient experience. The ADR is classified as certain, probable, possible, or questionable based on the total score that is assigned to each response (Naranjo et al., 1981).

Because of its ease of use and repeatability, the Naranjo algorithm is frequently employed in clinical research and hospital environments. In contrast to systems that rely solely on judgment, it offers a more objective approach. Nevertheless, it has drawbacks, such as its incapacity to take into consideration complicated clinical situations, medication interactions, and patient population diversity. Furthermore, some questions might not be relevant in every situation, especially when doing retrospective analyses (Belhekar et al., 2014; Naranjo et al., 1981).

6.4 Limitations of Current Methods

Existing approaches for assessing causality are widely used, but they have a number of drawbacks. The use of subjective judgment, which can result in inter-observer variability and inconsistent evaluation, is one of the main problems. Additionally, many approaches may not sufficiently address multifactorial causes involving drug interactions and comorbidities and

lack sensitivity in identifying uncommon or delayed adverse drug reactions (ADRs) (Agbabiaka et al., 2008; Theophile et al., 2013).

Applying standardized algorithms to real-world clinical situations, where comprehensive data is frequently unavailable, is another drawback. Causality assessment can be made more difficult by elements including insufficient patient histories, a lack of rechallenge data, and underreporting of adverse drug reactions. Furthermore, the majority of current instruments were created using conventional pharmacological principles and might not adequately represent the complexity of contemporary treatments, such as biologics and customized medicine (Macedo et al., 2006; Belhekar et al., 2014).

There is increasing interest in using cutting-edge techniques like probabilistic models, Bayesian methodologies, and artificial intelligence into causality evaluation in order to get beyond these restrictions. These new methods could increase pharmacovigilance systems' overall efficacy, decrease subjectivity, and improve accuracy (Theophile et al., 2013).

7. Role of Pharmacovigilance in ADR Management

Because it allows for ongoing medication monitoring and prompt measures to lower related risks, pharmacovigilance is essential to the management of adverse drug reactions (ADRs). It includes a broad variety of tasks, including as identifying, evaluating, preventing, and communicating drug-related side effects. In all healthcare settings, effective pharmacovigilance systems provide better clinical outcomes, well-informed regulatory choices, and increased patient safety (Pirmohamed et al., 2004; Waller, 2017).

7.1 Early Detection and Prevention

One of the main goals of pharmacovigilance is the early detection of adverse drug reactions. Potential safety signals can be found early on by methodically gathering and analyzing safety data from clinical studies, spontaneous reporting systems, and healthcare databases. This enables regulatory bodies and healthcare professionals to intervene quickly before negative consequences proliferate (Pirmohamed et al., 2004; Hauben & Zhou, 2003).

Updating prescribing information, limiting drug usage in high-risk populations, and publishing safety warnings are examples of preventive interventions based on early detection. By taking these steps, the overall safety profile of medications is improved and the frequency of ADRs is decreased. For newly released medications, early detection is especially crucial because pre-marketing data may be insufficient to identify uncommon or persistent side effects (Waller, 2017; Edwards, 2017).

7.2 Risk Minimization Strategies

Risk minimization techniques are used to lessen the possibility and severity of adverse drug reactions (ADRs) while preserving the medications' therapeutic advantages. Dosage modifications, contraindications, cautions and warnings, and patient and healthcare professional education programs are some examples of these tactics (Giezen et al., 2007).

For some medications, regulatory bodies frequently mandate the creation of risk management plans (RMPs), which outline steps to recognize, describe, and reduce hazards. To guarantee safe medicine usage, other strategies like patient monitoring requirements, restricted distribution programs, and safety labeling modifications are also employed. Active stakeholder collaboration and ongoing assessment of pharmacovigilance data are essential for effective risk mitigation (Rombach et al., 2016; Giezen et al., 2007).

7.3 Medication Error Prevention

Pharmacovigilance places a lot of emphasis on medication errors since they are a major contributor to avoidable adverse drug events. These mistakes can happen at any point during the prescription, dispensing, administration, and monitoring phases of the pharmaceutical use process. Pharmacovigilance systems facilitate the creation of measures to prevent recurrence by identifying patterns of drug errors and their underlying causes (Ferner & Aronson, 2006).

Improving prescription labeling and packaging, putting electronic prescribing systems in place, and educating and training medical personnel are all interventions to reduce medication errors. As part of pharmacovigilance efforts, reporting and evaluating medication errors lowers the burden of avoidable injury and promotes better pharmaceutical practices (Aronson, 2009; Ferner & Aronson, 2006).

7.4 Enhancing Patient Safety

One of the main objectives of pharmacovigilance is to improve patient safety. Pharmacovigilance systems assist make sure that the advantages of medications outweigh any potential hazards by detecting and controlling drug-related risks. This entails carrying out the necessary regulatory activities, assessing risk-benefit profiles, and continuously monitoring drug safety data (Leape et al., 2009).

By encouraging the reporting of adverse drug reactions (ADRs) and promoting cooperation between medical professionals, regulatory bodies, and patients, pharmacovigilance also fosters a culture of safety within healthcare systems. Better patient outcomes and a lower frequency of adverse events are further benefits of increased medication safety awareness and education (Waller, 2017; Leape et al., 2009).

7.5 Post-Marketing Surveillance

A crucial part of pharmacovigilance, post-marketing surveillance—also referred to as Phase IV monitoring—focuses on the safety of medications after they have received approval for use. Pre-marketing clinical trials may miss uncommon, long-term, or population-specific side effects since they are carried out in controlled settings with small sample sizes (Moore et al., 2018).

Spontaneous reporting, observational studies, and database analysis are examples of post-marketing pharmacovigilance operations that track drug safety in practical contexts. These initiatives facilitate the discovery of fresh safety issues and assist with regulatory measures like label revisions, usage limitations, or, if required, drug withdrawal. Thus, post-marketing surveillance guarantees that drug safety is continuously assessed over the course of its lifecycle (Moore et al., 2018; Waller, 2017).

8. Tools and Technologies in Pharmacovigilance

By increasing the effectiveness, precision, and promptness of adverse drug reaction (ADR) identification and management, technological developments have profoundly changed pharmacovigilance. Large-scale databases, statistical techniques, artificial intelligence (AI), and digital reporting platforms are all used in modern pharmacovigilance to improve medication safety monitoring and decision-making procedures (Bate & Edwards, 2006; Harpaz et al., 2012).

8.1 Databases

Pharmacovigilance databases are crucial resources for gathering and organizing ADR reports from many sources. The Uppsala Monitoring Center maintains VigiBase, one of the most well-known databases in the world. Millions of Individual Case Safety Reports (ICSRs) from member nations taking part in the WHO Program for International Drug Monitoring are stored in VigiBase (Lindquist, 2008).

Large-scale medication safety data analysis is made easier by these databases, which also aid in the discovery of uncommon and hitherto undetected side effects. Other significant databases that support regional pharmacovigilance initiatives are FAERS (USA) and EudraVigilance (Europe). Comprehensive safety assessments across varied populations are made possible by the integration of such datasets, which also improves international collaboration (Sakaeda et al., 2013; Alvarez et al., 2010).

8.2 Signal Detection and Data Mining

A crucial aspect of pharmacovigilance is signal detection, which is aided by sophisticated data mining methods used on sizable ADR datasets. To find signals suggesting possible relationships between medications and adverse events, statistical techniques like

disproportionality analysis—including proportional reporting ratios (PRR) and Bayesian approaches—are frequently employed (Bate & Edwards, 2006).

Large datasets can be effectively analyzed using data mining techniques, which makes it possible to identify safety signs early on that conventional methods can miss. These methods enhance signal detection's sensitivity and specificity and aid in regulatory decision-making. To differentiate genuine relationships from coincidental observations, however, rigorous clinical evaluation is necessary for signal interpretation (Harpaz et al., 2012; Norén et al., 2008).

8.3 Role of Artificial Intelligence

Pharmacovigilance is progressively incorporating artificial intelligence (AI) to increase signal detection, automate procedures, and improve data analysis. To find possible ADRs, machine learning algorithms can examine vast amounts of organized and unstructured data, such as clinical notes, social media, and scholarly publications (Bate & Hobbiger, 2021).

By extracting pertinent safety information from textual data sources, natural language processing (NLP) techniques increase the effectiveness of signal detection and case processing. Predictive modeling is also supported by AI-driven systems, enabling proactive risk assessment and early detection of possible safety issues. Despite its benefits, issues with data quality, algorithm transparency, and regulatory approval must be resolved before it can be widely used (Koutkias et al., 2018; Bate & Hobbiger, 2021).

8.4 Digital Reporting Tools and Mobile Applications

The reporting and management of ADRs has been completely transformed by digital reporting tools and mobile applications. These platforms increase reporting rates and data accuracy by making it simple and quick for patients and healthcare professionals to submit ADR reports. To improve public participation and enable immediate reporting, some national pharmacovigilance programs have created mobile applications (Inácio et al., 2017).

Pharmacovigilance efforts are more efficient and less time-consuming when data collection and integration with central databases are streamlined by electronic reporting systems. Digital tools also facilitate real-time monitoring, automated workflows, and quick safety information sharing. The use of these technologies has improved drug safety surveillance and greatly reinforced pharmacovigilance systems (Avery et al., 2011; Koutkias et al., 2018).

9. Challenges in Pharmacovigilance

Pharmacovigilance has made significant strides, but a number of enduring issues still limit its ability to guarantee the best possible drug safety. Adverse drug reaction (ADR) identification,

assessment, and prevention are hampered by systemic, technical, educational, and regulatory limitations. Improving patient safety worldwide and increasing the dependability of pharmacovigilance systems depend on resolving these problems (Lopez-Gonzalez et al., 2009; Alshammari & Alshakka, 2020).

9.1 Underreporting of ADRs

One of the biggest problems with pharmacovigilance systems around the world is still underreporting. According to studies, only 5–10% of all ADRs are reported, which seriously compromises the early detection of safety signals (Hazell & Shakir, 2006). For uncommon, delayed, or severe adverse responses that primarily rely on spontaneous reporting systems for identification, this problem is especially worrisome.

Underreporting is caused by a number of circumstances, such as a lack of time, confusion regarding the causative relationship between drug and reaction, fear of legal ramifications, and a lack of incentives or motivation among medical professionals. Furthermore, complicated reporting processes and inadequate regulatory authority feedback deter reporting (Lopez-Gonzalez et al., 2009).

Efforts have been made to solve this issue by introducing online and mobile reporting platforms, streamlining reporting methods, and putting awareness campaigns into place. Reporting rates and data completeness can be greatly increased by promoting a non-punitive reporting culture and incorporating pharmacovigilance into standard clinical practice (Alshammari & Alshakka, 2020).

9.2 Lack of Awareness

ADR reporting and monitoring are severely hampered by patients' and healthcare workers' lack of knowledge and insufficient training in pharmacovigilance. According to Toklu and Uysal (2008), many healthcare professionals lack a thorough understanding of reporting protocols, the significance of pharmacovigilance, or the effects of ADR reporting on public health.

The lack of pharmacovigilance education in medical, pharmacy, and nursing curriculum exacerbates this disparity. Because of this, medical personnel could overlook or fail to record adverse drug reactions (ADRs), particularly if they are moderate or unusual. In a similar vein, patients frequently don't know about adverse drug reactions (ADRs) or that they can report them immediately (Avery et al., 2011).

It is crucial to raise awareness through ongoing medical education, workshops, and training initiatives. Pharmacovigilance systems can be strengthened by increasing awareness and

participation through patient engagement programs and public health campaigns (Toklu & Uysal, 2008).

9.3 Data Quality Issues

The quality of the data gathered has a major impact on how successful pharmacovigilance systems are. ADR reports, however, frequently have problems such missing clinical facts, duplication, inconsistency, and incomplete information. Accurate causality assessment and signal identification may be hampered by missing information on patient demographics, drug dosage, length of therapy, and concurrent drugs (Bergvall et al., 2014).

False-positive or false-negative signals resulting from poor data quality might impact patient safety and regulatory decisions. Data integration and analysis are further complicated by differences in reporting requirements between nations and organizations (Norén et al., 2008).

Standardized reporting formats like Individual Case Safety Reports (ICSRs) and coding systems like MedDRA are frequently utilized to enhance data quality. Errors can be decreased and data completeness improved by implementing electronic reporting systems with integrated validation checks. Maintaining high-quality pharmacovigilance data also requires frequent data audits and ongoing training for reports (Bergvall et al., 2014).

9.4 Regulatory Challenges

Variations in national policies, regulations, and reporting requirements give rise to regulatory issues in pharmacovigilance. The implementation of consistent safety measures worldwide may be challenging due to these variances, which may result in inconsistent data collection, processing, and interpretation (Wisniewski et al., 2020).

Regulatory control has become more complicated due to the quick introduction of novel therapeutic modalities such biologics, gene therapies, and combination products. These goods frequently need long-term safety assessment and specialized monitoring techniques, which may not be sufficiently covered by current regulatory frameworks (Dal Pan, 2012).

Regulatory bodies must also strike a balance between the necessity of prompt access to cutting-edge treatments and the need for careful safety assessment. Patient safety may be impacted by regulatory action delays or a lack of agency collaboration. To address these obstacles, worldwide harmonization initiatives like those spearheaded by ICH must be strengthened, and regulatory authorities must work together more effectively (Wisniewski et al., 2020).

9.5 Issues in Developing Countries

Developing nations have particular difficulties putting in place efficient pharmacovigilance systems. ADR monitoring and reporting efforts are severely hampered by a lack of funding,

poor infrastructure, and untrained staff. Pharmacovigilance systems are still in their infancy in many areas, which leads to low reporting rates and inadequate data for analysis (Olsson et al., 2019).

Pharmacovigilance initiatives are further complicated by cultural and socioeconomic variables, such as inadequate health literacy, dependence on traditional medicine, and mistrust of healthcare systems. Adoption of contemporary reporting systems is further hampered by restricted access to digital technologies and healthcare facilities (Ampadu et al., 2016).

International assistance and capacity-building programs are crucial to resolving these problems. In settings with limited resources, strengthening national pharmacovigilance centers, enhancing training programs, and utilizing mobile technology can improve ADR reporting and monitoring. Building viable pharmacovigilance systems in poor nations requires cooperation between international organizations and local authorities (Olsson et al., 2019).

10. Future Perspectives

Technological developments, more data accessibility, and a move toward patient-centered healthcare are all contributing to the rapid evolution of pharmacovigilance in the future, allowing for a change from reactive to proactive medication safety monitoring (Arlett et al., 2019). Automated case processing, enhanced signal identification, and real-time analysis of many data sources, including wearables, social media, and electronic health records, are all made possible by the combination of artificial intelligence (AI) with big data analytics (Bate & Hobbiger, 2021). Furthermore, by identifying genetic markers impacting drug response and vulnerability to adverse drug reactions (ADRs), pharmacogenomics enhances risk prediction and therapeutic outcomes, supporting personalized therapy (Roden et al., 2019).

Furthermore, by offering insights into medication safety in routine clinical practice and facilitating the identification of uncommon and long-term side effects across larger populations, real-world evidence (RWE) is becoming more and more significant (Sherman et al., 2016). Simultaneously, pharmacovigilance systems are being strengthened by international cooperation between regulatory bodies, medical professionals, and organizations like the World Health Organization through data exchange, standardization, and coordinated regulatory measures (Edwards, 2017). When combined, these developments could result in pharmacovigilance systems that are more effective, predictive, and patient-specific, thereby enhancing public health outcomes (Arlett et al., 2019).

11. Conclusion

Pharmacovigilance, which guarantees the safe and sensible use of medications throughout their lifecycle, has developed into a crucial part of contemporary healthcare systems. It is essential for identifying, evaluating, comprehending, and preventing adverse drug reactions (ADRs), which reduces medication-related dangers and enhances therapeutic results. Through enhanced data sharing, signal detection, and regulatory coordination, the integration of national systems like PvPI with international programs like the WHO Programme for International Drug Monitoring has bolstered drug safety surveillance.

The effectiveness and precision of pharmacovigilance operations have been greatly improved by developments in digital health technology, including as electronic health records, mobile reporting apps, big data analytics, and artificial intelligence. These developments facilitate evidence-based regulatory decision-making and allow for the early detection of safety warnings. However, obstacles like underreporting, ignorance, poor data quality, and little resources in impoverished nations still prevent pharmacovigilance from operating at its best.

To ensure pharmaceutical safety, pharmacovigilance systems must be strengthened through international cooperation, better education, technology integration, and patient and healthcare professional involvement. In addition to lessening the incidence of adverse drug reactions (ADRs), a strong pharmacovigilance framework greatly enhances global pharmacotherapy outcomes and protects public health.

12. Acknowledgement

The authors would like to express their sincere gratitude to their mentors and colleagues for their invaluable guidance and support during the preparation of this review.

13. Conflict of Interest

The authors declare that there is no conflict of interest regarding the publication of this review.

14. References

- Agbabiaka, T. B., Savović, J., & Ernst, E. (2008). Methods for causality assessment of adverse drug reactions: A systematic review. *Drug Safety, 31*(1), 21–37.
- Alshammari, T. M., & Alshakka, M. (2020). Pharmacovigilance system in developing countries: Challenges and opportunities. *Saudi Pharmaceutical Journal, 28*(5), 629–632.
- Alvarez, Y., Hidalgo, A., Maignen, F., & Slattery, J. (2010). Validation of statistical signal detection procedures in EudraVigilance. *Drug Safety, 33*(6), 475–487.

- Ampadu, H. H., Hoekman, J., de Bruin, M. L., Pal, S. N., Olsson, S., Sartori, D., & Leufkens, H. G. (2016). Organizational capacities of national pharmacovigilance centres in Africa. *Drug Safety, 39*(7), 655–664.
- Arlett, P., Kjær, J., Broich, K., & Cooke, E. (2019). Real-world evidence in pharmacovigilance. *Clinical Pharmacology & Therapeutics, 106*(1), 30–35.
- Aronson, J. K. (2009). Medication errors: Definitions and classification. *British Journal of Clinical Pharmacology, 67*(6), 599–604.
- Aronson, J. K. (2012). *Meyler's side effects of drugs: The international encyclopedia of adverse drug reactions and interactions* (16th ed.). Elsevier.
- Avery, A. J., Anderson, C., Bond, C. M., Fortnum, H., Gifford, A., Hannaford, P. C., Hazell, L., Krska, J., Lee, A. J., McLernon, D. J., Murphy, E., Shakir, S., & Watson, M. C. (2011). Evaluation of patient reporting of adverse drug reactions to the UK Yellow Card Scheme. *British Journal of Clinical Pharmacology, 73*(2), 300–308.
- Banerjee, I., & Mondal, S. (2019). Pharmacovigilance: An overview. *International Journal of Pharmaceutical Sciences Review and Research, 58*(2), 1–6.
- Bate, A., & Edwards, I. R. (2006). Data mining techniques in pharmacovigilance. *Drug Safety, 29*(10), 939–948.
- Bate, A., & Hobbiger, S. F. (2021). Artificial intelligence in pharmacovigilance: Opportunities and challenges. *Drug Safety, 44*(3), 233–241
- Belhekar, M. N., Taur, S. R., & Munshi, R. P. (2014). A study of agreement between the Naranjo algorithm and WHO-UMC criteria for causality assessment of adverse drug reactions. *Indian Journal of Pharmacology, 46*(1), 117–120.
- Bergvall, T., Norén, G. N., & Lindquist, M. (2014). vigiGrade: A tool to identify well-documented individual case reports and highlight systematic data quality issues. *Drug Safety, 37*(1), 65–77.
- Coloma, P. M., Trifirò, G., Patadia, V., & Sturkenboom, M. (2013). Postmarketing safety surveillance using electronic healthcare records. *Drug Safety, 36*(3), 183–197.
- Dal Pan, G. J. (2012). Ongoing challenges in pharmacovigilance. *Drug Safety, 35*(1), 1–3.
- Edwards, I. R. (2017). A new era of pharmacovigilance: Reflections on its development. *Drug Safety, 40*(12), 1101–1103.
- Edwards, I. R., & Aronson, J. K. (2000). Adverse drug reactions: Definitions, diagnosis, and management. *The Lancet, 356*(9237), 1255–1259.

- Ferner, R. E., & Aronson, J. K. (2006). Clarification of terminology in medication errors. *Drug Safety, 29*(11), 1011–1022.
- Giezen, T. J., Mantel-Teeuwisse, A. K., & Straus, S. M. (2007). Risk minimization activities in Europe: Current status and future directions. *Drug Safety, 30*(7), 569–580.
- Golder, S., Loke, Y. K., & Wright, K. (2011). Methods for assessing adverse effects in systematic reviews. *BMC Medical Research Methodology, 11*, 1–9.
- Hauben, M., & Zhou, X. (2003). Quantitative methods in pharmacovigilance. *Drug Safety, 26*(3), 159–186.
- Harpaz, R., DuMouchel, W., LePendu, P., Bauer-Mehren, A., Ryan, P., & Shah, N. H. (2012). Performance of pharmacovigilance signal detection algorithms. *Clinical Pharmacology & Therapeutics, 93*(6), 539–546.
- Hartigan-Go, K. (2018). The importance of pharmacovigilance in ensuring drug safety. *Bulletin of the World Health Organization, 96*(7), 506–507.
- Hazell, L., & Shakir, S. A. (2006). Under-reporting of adverse drug reactions: A systematic review. *Drug Safety, 29*(5), 385–396.
- Hripcsak, G., Duke, J. D., Shah, N. H., Reich, C. G., Huser, V., Schuemie, M. J., Suchard, M. A., Park, R. W., Wong, I. C., Rijnbeek, P. R., van der Lei, J., Pratt, N., Norén, G. N., Li, Y. C., Stang, P. E., Madigan, D., & Ryan, P. B. (2015). Observational Health Data Sciences and Informatics (OHDSI). *Studies in Health Technology and Informatics, 216*, 574–578.
- Inácio, P., Cavaco, A., & Airaksinen, M. (2017). The value of patient reporting to pharmacovigilance systems. *British Journal of Clinical Pharmacology, 83*(2), 227–246.
- International Council for Harmonisation (ICH). (2016). *ICH E2B (R3) guideline: Electronic transmission of individual case safety reports*.
- Kalaiselvan, V., Thota, P., & Singh, G. N. (2019). Pharmacovigilance Programme of India. *Indian Journal of Pharmacology, 51*(4), 227–232.
- Koutkias, V., Stafylas, P., & Jaulent, M. C. (2018). Leveraging artificial intelligence in pharmacovigilance. *Expert Opinion on Drug Safety, 17*(10), 1049–1057.
- Kurz, X., & Van Erps, J. (2017). Pharmacovigilance in the European Union. *Therapeutic Advances in Drug Safety, 8*(8), 297–305.
- Lazarou, J., Pomeranz, B. H., & Corey, P. N. (1998). Incidence of adverse drug reactions in hospitalized patients. *JAMA, 279*(15), 1200–1205.

- Lindquist, M. (2008). VigiBase, the WHO global ICSR database system. *Drug Information Journal, 42*(5), 409–419.
- Lopez-Gonzalez, E., Herdeiro, M. T., & Figueiras, A. (2009). Determinants of under-reporting of adverse drug reactions. *Drug Safety, 32*(1), 19–31.
- Macedo, A. F., Marques, F. B., & Ribeiro, C. F. (2006). Causality assessment of adverse drug reactions. *Pharmacoepidemiology and Drug Safety, 15*(9), 613–619.
- Mann, R. D., & Andrews, E. B. (2007). *Pharmacovigilance* (2nd ed.). Wiley-Blackwell.
- McBride, W. G. (1961). Thalidomide and congenital abnormalities. *The Lancet, 278*(7216), 1358.
- Moore, T. J., Furberg, C. D., & Mattison, D. R. (2018). Postmarketing drug safety surveillance. *JAMA, 320*(9), 929–930.
- Norén, G. N., Bate, A., Orre, R., & Edwards, I. R. (2008). Extending signal detection methods. *Statistics in Medicine, 27*(16), 3057–3070.
- Olsson, S., Pal, S. N., & Dodoo, A. (2019). Pharmacovigilance in resource-limited countries. *Expert Review of Clinical Pharmacology, 12*(5), 449–460.
- Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A. K., Walley, T. J., Farrar, K., Park, B. K., & Breckenridge, A. M. (2004). Adverse drug reactions as a cause of hospital admission. *BMJ, 329*(7456), 15–19.
- Roden, D. M., McLeod, H. L., Relling, M. V., Williams, M. S., Mensah, G. A., Peterson, J. F., & Van Driest, S. L. (2019). Pharmacogenomics. *The Lancet, 394*(10197), 521–532.
- Rombach, I., Rivero-Arias, O., Gray, A. M., Jenkinson, C., & Alfirevic, Z. (2016). Risk minimization strategies. *Pharmacoepidemiology and Drug Safety, 25*(9), 1080–1087.
- Routledge, P. A., O'Mahony, M. S., & Woodhouse, K. W. (2004). Adverse drug reactions in elderly patients. *British Journal of Clinical Pharmacology, 57*(2), 121–126.
- Sakaeda, T., Tamon, A., Kadoyama, K., & Okuno, Y. (2013). Data mining of FAERS database. *International Journal of Medical Sciences, 10*(7), 796–803.
- Schneeweiss, S., & Avorn, J. (2005). Health care utilization databases for research. *Journal of Clinical Epidemiology, 58*(4), 323–337.
- Sherman, R. E., Anderson, S. A., Dal Pan, G. J., et al. (2016). Real-world evidence. *New England Journal of Medicine, 375*(23), 2293–2297.

- Singh, S., Loke, Y. K., & Spangler, J. G. (2018). Risk management in pharmacovigilance. *BMJ, 362*, k3289.
- Strom, B. L., & Kimmel, S. E. (2019). *Textbook of pharmacoepidemiology* (2nd ed.). Wiley.
- Theophile, H., Andrejak, M., & Miremont-Salamé, G. (2013). Comparison of causality assessment methods. *Fundamental & Clinical Pharmacology, 27*(6), 633–638.
- Toklu, H. Z., & Uysal, M. K. (2008). Awareness of pharmacovigilance. *Journal of Clinical Pharmacy and Therapeutics, 33*(5), 507–514.
- Vargesson, N. (2015). Thalidomide-induced teratogenesis. *Birth Defects Research Part C, 105*(2), 140–156.
- Waller, P. (2017). *An introduction to pharmacovigilance* (2nd ed.). Wiley-Blackwell.
- Wisniewski, A. F., Bate, A., Bousquet, C., et al. (2020). Good signal detection practices. *Drug Safety, 43*(3), 203–210.
- World Health Organization. (2002). *The importance of pharmacovigilance: Safety monitoring of medicinal products*. WHO Press.
- World Health Organization. (2012). *Cohort event monitoring (CEM) for active safety surveillance*. WHO Press.
- WHO-UMC. (2018). *The use of the WHO-UMC system for standardized case causality assessment*. Uppsala Monitoring Centre.